Matinas BioPharma Holdings Inc
AMEX:MTNB
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
M
|
Matinas BioPharma Holdings Inc
AMEX:MTNB
|
4m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
390.9B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
192.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
78B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Matinas BioPharma Holdings Inc
Glance View
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).
